文献速递前列腺癌

前列腺特异性膜抗原靶向18F-DCFPyL PET/CT用于高危前列腺癌术前分期

Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.
PubMed 文献 · J Urol · 2017-07-20

这项前瞻性II期单中心研究纳入25例临床局限高危/极高危前列腺癌患者,在根治性前列腺切除加标准化盆腔淋巴结清扫前行18F-DCFPyL PET/CT,以手术病理为参考标准评估盆腔淋巴结分期诊断准确性;患者水平敏感度71.4%、特异度88.9%,淋巴结包水平敏感度66.7%、特异度92.7%,作者认为结果支持开展更大样本研究。

要点

  • 25例高危前列腺癌患者中,7例(28%)手术病理证实1枚及以上淋巴结阳性。
  • 患者水平诊断:敏感度71.4%(95%CI 29.0-96.3),特异度88.9%(95%CI 65.3-98.6)。
  • 淋巴结包水平诊断:敏感度66.7%(95%CI 29.9-92.5),特异度92.7%(95%CI 80.1-98.5)。

核心结论

  • 18F-DCFPyL PET/CT可准确检出传统影像判断为临床局限性疾病患者的前列腺癌病灶。
  • 作者认为结果支持开展更大样本研究以更精确界定该新型分子影像检查的诊断准确性。

研究设计与样本

  • 前瞻性II期单中心研究,纳入临床局限高危或极高危前列腺癌男性,根治性前列腺切除加标准化盆腔淋巴结清扫前行18F-DCFPyL PET/CT。
  • 扫描由2名设盲核医学阅片者判读,评估阅片者间差异及盆腔淋巴结分期诊断准确性,以手术病理为参考标准。
  • 共25例男性提供可分析数据。

主要发现

  • 25例中7例(28%)手术病理发现1枚及以上阳性淋巴结。
  • 所有成像患者前列腺内均见放射性示踪剂摄取部位。
  • 2名阅片者在22例(88%)中识别出相同数量的前列腺病灶,且这些病例两次判读均至少有1个共同前列腺内病灶。
  • 2名阅片者对50个淋巴结包中的46个(92%)给出相同N分期。
  • 对少数不一致判读进行核对后,7例(28%)盆腔内发现1处及以上符合N1疾病的放射性示踪剂摄取部位;3例(12%)有M1a疾病证据。

关键数值与推荐

  • 患者水平:敏感度71.4%(95%CI 29.0-96.3),特异度88.9%(95%CI 65.3-98.6)。
  • 淋巴结包水平:敏感度66.7%(95%CI 29.9-92.5),特异度92.7%(95%CI 80.1-98.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要更大样本研究以更精确界定该新型分子影像检查的诊断准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We prospectively evaluated the diagnostic performance of prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography/computerized tomography in the preoperative staging of men at high risk for harboring metastatic prostate cancer despite a negative conventional staging evaluation. MATERIALS AND METHODS: Men with clinically localized high or very high risk prostate cancer were imaged with 18F-DCFPyL positron emission tomography/computerized tomography before undergoing radical prostatectomy with standardized pelvic lymph node dissection. The scans were interpreted by 2 blinded nuclear medicine readers and assessed for interreader variability as well as diagnostic accuracy for pelvic lymph node staging. Surgical pathology served as the reference standard to which 18F-DCFPyL scan findings were compared. RESULTS: A total of 25 men contributed analyzable data to this study. Seven of these patients (28%) were found to have 1 or more positive lymph nodes on surgical pathology. Sites of radiotracer uptake were identified in the prostate of all imaged patients. The 2 readers identified the same number of prostatic lesions in 22 patients (88%), of whom all had at least 1 intraprostatic lesion in common between the 2 reads. Additionally, the readers assigned the same N stage to 46 of 50 individual lymph node packets (92%). Following reconciliation of the relatively few discordant imaging reads, 7 patients (28%) were found to have 1 or more sites of radiotracer uptake in the pelvis consistent with N1 disease, resulting in 71.4% sensitivity (95% CI 29.0-96.3) and 88.9% specificity (95% CI 65.3-98.6). Analysis at the level of individual nodal packets resulted in 66.7% sensitivity (95% CI 29.9-92.5) and 92.7% specificity (95% CI 80.1-98.5). Three men (12%) had evidence of M1a disease. CONCLUSIONS: 18F-DCFPyL positron emission tomography/computerized tomography allowed for accurate detection of prostate cancer sites in men believed to have clinically localized disease based on conventional imaging. Our results support the need for a larger study to more precisely define the diagnostic accuracy of this novel molecular imaging test.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Gorin MA, Rowe SP, Patel HD, et al. Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol. 2017. PMID: 28736318. doi:10.1016/j.juro.2017.07.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。